Overview
Hiromitsu Sakai practices practicing medicine in Matsue, Japan.
Their clinical expertise encompasses Leukocytosis, Relapsing Polychondritis, Pneumonia, and Squamous Cell Lung Carcinoma.
They are actively involved in clinical research, co-authoring 15 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Hiromitsu Sakai
Is Hiromitsu Sakai a top-rated expert for Leukocytosis?
MediFind is an objective health platform that identifies experts based on real-world data. Hiromitsu Sakai is classified as an Experienced expert for Leukocytosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Hiromitsu Sakai participate in research or clinical trials?
Yes. Hiromitsu Sakai has published 15 articles and abstracts on conditions like Leukocytosis. You can view a list of Hiromitsu Sakai's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- LeukocytosisSakai isExperienced. Learn about Leukocytosis.
- PneumoniaSakai isExperienced. Learn about Pneumonia.
- Relapsing PolychondritisSakai isExperienced. Learn about Relapsing Polychondritis.
- Squamous Cell Lung CarcinomaSakai isExperienced. Learn about Squamous Cell Lung Carcinoma.